KR890001533A - 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용 - Google Patents

레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용 Download PDF

Info

Publication number
KR890001533A
KR890001533A KR1019870007874A KR870007874A KR890001533A KR 890001533 A KR890001533 A KR 890001533A KR 1019870007874 A KR1019870007874 A KR 1019870007874A KR 870007874 A KR870007874 A KR 870007874A KR 890001533 A KR890001533 A KR 890001533A
Authority
KR
South Korea
Prior art keywords
composition
active ingredient
ldme
mixed
levodopa methyl
Prior art date
Application number
KR1019870007874A
Other languages
English (en)
Other versions
KR950002150B1 (ko
Inventor
키에시 파올로
Original Assignee
원본미기재
키에시 파프마세우티시 에스·피·에이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IT20737/86A external-priority patent/IT1190342B/it
Priority claimed from IT19221/87A external-priority patent/IT1203321B/it
Application filed by 원본미기재, 키에시 파프마세우티시 에스·피·에이 filed Critical 원본미기재
Publication of KR890001533A publication Critical patent/KR890001533A/ko
Application granted granted Critical
Publication of KR950002150B1 publication Critical patent/KR950002150B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음

Description

레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (11)

  1. 유효 성분으로서 레보도파 메틸 에스테르(LDME) 및 제약 담체 또는 희석제를 함유하는 제약 조성물.
  2. 제1항에 있어서,도파민 동근군, 콜린작용 억제제, 항우울증제, 말초 디카르복실라제 억제제, MAD-B억제제 또는 이들의 혼합물로부터 선택되는 다른 유효 효소와 함께 LDME를 함유하는 조성물.
  3. 제1항 내지 제2항에 있어서, 유효 성분으로서 LDME만을 함유하거나 또는 액상 담체 또는 희석제를 혼합시킨 용액 조성물.
  4. 제1항 내지 제2항에 있어서, 유효 성분으로서 LDME만을 함유하거나 또는 액상 담체 또는 희석제를 혼합시킨 고상 형태의 조성물.
  5. 제1항 내지 제4항에 있어서, 경구, 협측, 설하, 직장, 비경구, 임의의 주입직 시스템을 사용하여 피하 또는 복강내 경로로 투입되는 조성물.
  6. 전항중 어느 하나의 항에 있어서, 고상 형태일 경우, 단위 투여량 당 유효 성분을 100 내지 1.000mg 함유하거나, 또는 액상 형태일 경우, 유효소를 50 내지 400mg/ml 함유하는 조성물.
  7. 제2항 내지 제4항에 있어서, 단위 투여량 당 레보도파 메틸 에스테르를 100 내지 30mg 함유하고, 벤세라지드 또는 카르비도파 또는 데프레닐이 각각 2:1 내지 5:1, 4:1 내지 20:1, 20:1, 20:1 내지 100:1 의 비율로 혼합되거나 또는 이들의 혼합물과 혼합시킨 조성물.
  8. 제2항 내지 제3항에 있어서, 레보도파 메틸 에스테르를 50 내지 40mg/ml 함유하고, 벤세라지드 또는 카르비도파 또는 데프레닐이 각각 2:1 내지 10:1, 4:1 내지 20:1, 20:1, 20:1 내지 100:1 의 비율로 혼합되거나 또는 이들의 혼합물과 혼합시킨 조성물.
  9. 전항 중 어느 하나의 항에 있어서, 유효 성분이 연장된 방식 또는 축차(逐次) 방색으로 방출되는 것을 특징으로 하는 조성물.
  10. 전항 중 어느 하나의 항에 있어서, 위장 조직을 바이패스하도록 투여되는 조성물.
  11. 피킨슨병 및 관련된 신경학적 증후군 치료에 유용한 의약품 제조를 위한 LDME의 용도.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870007874A 1986-06-10 1987-07-21 레보도파 메틸에스테르를 함유하는 제약 조성물 KR950002150B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IT20737/86A IT1190342B (it) 1986-06-10 1986-06-10 Composizioni farmaceutiche contenenti levodopa metil estere,loro procedimento di preparazione e relative applicazioni terapeutiche
IT20737A/86 1986-06-10
IT19221A/87 1987-01-30
IT19221/87A IT1203321B (it) 1987-01-30 1987-01-30 Composizioni farmaceutiche contenenti levodora metil estere,loro prodecimento di preparazione e relative applicazioni terapeutiche

Publications (2)

Publication Number Publication Date
KR890001533A true KR890001533A (ko) 1989-03-27
KR950002150B1 KR950002150B1 (ko) 1995-03-14

Family

ID=26327098

Family Applications (2)

Application Number Title Priority Date Filing Date
KR870005806A KR880000092A (ko) 1986-06-10 1987-06-09 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
KR1019870007874A KR950002150B1 (ko) 1986-06-10 1987-07-21 레보도파 메틸에스테르를 함유하는 제약 조성물

Family Applications Before (1)

Application Number Title Priority Date Filing Date
KR870005806A KR880000092A (ko) 1986-06-10 1987-06-09 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용

Country Status (13)

Country Link
US (2) US4826875A (ko)
EP (1) EP0252290B1 (ko)
JP (1) JP2572768B2 (ko)
KR (2) KR880000092A (ko)
AT (1) ATE76747T1 (ko)
AU (1) AU605154B2 (ko)
CA (1) CA1303509C (ko)
DE (2) DE3779500T2 (ko)
ES (1) ES2042520T3 (ko)
GR (1) GR880300058T1 (ko)
HU (1) HUT43952A (ko)
NZ (1) NZ220631A (ko)
PT (1) PT85055B (ko)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983400A (en) * 1986-06-16 1991-01-08 Merck & Co., Inc. Controlled release combination of carbidopa/levodopa
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
SE9203594D0 (sv) * 1992-11-30 1992-11-30 Christer Nystroem Laekemedel i dispersa system
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
US5607969A (en) * 1992-12-24 1997-03-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem L-DOPA ethyl ester to treat Parkinson's disease
DE4325435A1 (de) * 1993-07-29 1995-02-02 Basf Ag Neue Wirkstoffkombination
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
US20050106241A1 (en) * 1995-02-03 2005-05-19 Brewer Francesca M. Pharmaceutical composition formulated for pre-gastric absorption of monoamine oxidase B inhibitors
EP0814789B2 (en) * 1995-03-02 2008-01-09 R.P. Scherer Technologies, Inc. Pharmaceutical compositions comprising monoamine oxidase b inhibitors
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
WO1996040085A2 (en) 1995-06-07 1996-12-19 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
IT1293764B1 (it) * 1997-07-23 1999-03-10 Chiesi Farma Spa Composizioni farmaceutiche sotto forma di compresse effervescenti contenenti un principio attivo instabile in presenza di acqua
US20040151768A1 (en) * 1997-07-23 2004-08-05 Chiesi Farmaceutici S.P.A. Pharmaceutical compositions containing an effervescent acid-base couple
CA2322878C (en) 1998-03-16 2008-05-06 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
CN1329487A (zh) 1998-11-10 2002-01-02 特瓦制药工业有限公司 包含l－多巴乙酯的可分散组合物
EP1137626A4 (en) 1998-11-10 2002-07-17 Teva Pharma METHOD FOR PRODUCING L-DOPA ETHYLESTER
US6506378B1 (en) 1998-12-16 2003-01-14 Arch Development Corporation Vesicular monoamine transporter gene therapy in Parkinson's disease
US6737547B1 (en) 1998-12-31 2004-05-18 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using N-acyl-1H-aminoindenes
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism
US20040010038A1 (en) * 2002-02-27 2004-01-15 Eran Blaugrund Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors
US8338420B1 (en) 2002-12-04 2012-12-25 Mitsubishi Tanabe Pharma Corporation Treatment of Parkinson's disease and enhancement of dopamine signal using PDE 10 inhibitor
US7101912B2 (en) 2002-12-06 2006-09-05 Xenoport, Inc. Carbidopa prodrugs and derivatives, and compositions and uses thereof
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
CA2523567A1 (en) * 2003-04-25 2004-11-11 Indevus Pharmaceuticals, Inc. Method for promoting uninterrupted sleep by administration of trospium chloride
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
DE602004031134D1 (de) * 2003-08-29 2011-03-03 Transform Pharmaceuticals Inc Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa
EP1675651A1 (en) * 2003-10-20 2006-07-05 Teva Pharmaceutical Industries Limited Composition and dosage form for sustained effect of levodopa
US7576073B2 (en) * 2004-05-28 2009-08-18 UNIVERSITé LAVAL Combined therapy for the treatment of parkinson's disease
US7323585B2 (en) * 2004-06-04 2008-01-29 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
PL1751087T3 (pl) * 2004-06-04 2012-11-30 Xenoport Inc Pochodne lewodopy oraz ich kompozycje i zastosowania
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060173074A1 (en) 2004-11-10 2006-08-03 Juha Ellmen Treatment of restless legs syndrome
WO2007002516A2 (en) * 2005-06-23 2007-01-04 Spherics, Inc. Improved dosage forms for movement disorder treatment
CA2657953A1 (en) * 2005-07-19 2007-01-25 University Of Rochester Alpha-synuclein antibodies and methods related thereto
US7563821B2 (en) 2005-12-05 2009-07-21 Xenoport, Inc. Levodopa prodrug mesylate, compositions thereof, and uses thereof
BRPI0620659A2 (pt) * 2005-12-09 2017-10-31 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd método para a prevenção do aparecimento de sintomas de uma doença neurodegenerativa em um indivíduo predisposto à doença neurodegenerativa, método de redução de stress oxidante no cérebro de um indivíduo afligido com stress oxidante, método de tratamento de um indivíduo afligido com a degeneração cognitiva suave e composição farmacêutica
PL1991522T3 (pl) * 2006-02-17 2017-07-31 Ratiopharm Gmbh Deuterowane pochodne katecholaminy i leki zawierające te związki
TW200744576A (en) * 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
TW200843731A (en) * 2006-12-21 2008-11-16 Xenoport Inc Catechol protected levodopa diester prodrugs, compositions, and methods of use
WO2008076458A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
AU2007338631A1 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
AU2008213772A1 (en) 2007-02-06 2008-08-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Composition comprising terpene compounds and methods for inhibiting nerve transmission
WO2009032202A1 (en) * 2007-08-29 2009-03-12 Nuon Therapeutics, Inc. Treatment of brain disorders
CN101283965B (zh) * 2007-10-26 2010-06-16 南京长澳医药科技有限公司 一种含左旋多巴甲酯的制剂及制备方法
KR101569604B1 (ko) 2007-12-28 2015-11-16 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
WO2010017626A1 (en) 2008-08-13 2010-02-18 Origin Biomed Inc. Compositions comprising terpene compounds for treating negative sensory phenomena
US9290445B2 (en) * 2008-10-20 2016-03-22 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US8286311B2 (en) 2008-10-31 2012-10-16 Jisook Paik Buckle
WO2010124185A1 (en) * 2009-04-23 2010-10-28 University Of Cincinnati Allantoin administration for the treatment of neurodegenerative disease and neurotrauma
RU2559083C9 (ru) * 2009-05-19 2016-01-20 Неуродерм Лтд Композиции для непрерывного введения ингибиторов допа-декарбоксилазы
EP2515876B1 (en) 2009-11-09 2016-01-06 XenoPort, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
MX348225B (es) 2010-11-15 2017-05-31 Neuroderm Ltd Administracion continua de levodopa, inhibidores de dopa decarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para la misma.
CA2823642A1 (en) * 2010-12-10 2012-06-14 Synagile Corporation Subcutaneously infusible levodopa prodrug compositions and methods of infusion
EP2854764B1 (en) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
WO2014164730A2 (en) 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Modulation of cellular dna repair activity to intercept malignancy
CN105188380B (zh) 2013-03-15 2017-08-15 百时美施贵宝公司 Lxr调节剂
EP2968275B1 (en) 2013-03-15 2017-11-29 Bristol-Myers Squibb Company Lxr modulators
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
DK3777833T3 (da) 2014-03-13 2023-12-18 Neuroderm Ltd Dopa-decarboxylase-inhibitorsammensætninger
EP3291872A4 (en) 2015-05-06 2019-02-13 SynAgile Corporation PHARMACEUTICAL SUSPENSIONS WITH ACTIVE SUBSTANCES, DEVICES FOR THEIR ADMINISTRATION AND METHOD FOR THEIR USE
MA52122A (fr) 2018-03-02 2021-04-28 Chiesi Farm Spa Formulation pharmaceutique pour administration intraduodénale comprenant de la mélévodopa et de la carbidopa
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2682871A (en) * 1970-03-24 1972-09-28 Sandler Merton Pharmaceutical compositions
JPS5157813A (en) * 1974-11-14 1976-05-20 Sankyo Co Ll dooba mataha sonojudotaiseizaino seiho
US4663349A (en) * 1985-12-30 1987-05-05 Merck & Co., Inc. Rectally absorbable form of L-dopa

Also Published As

Publication number Publication date
KR950002150B1 (ko) 1995-03-14
GR880300058T1 (en) 1988-10-18
CA1303509C (en) 1992-06-16
JPS6327428A (ja) 1988-02-05
EP0252290A2 (en) 1988-01-13
KR880000092A (ko) 1988-03-23
DE3779500T2 (de) 1993-01-21
PT85055A (pt) 1988-07-01
PT85055B (pt) 1994-10-31
DE252290T1 (de) 1988-06-09
JP2572768B2 (ja) 1997-01-16
NZ220631A (en) 1990-12-21
DE3779500D1 (de) 1992-07-09
EP0252290B1 (en) 1992-06-03
AU7405387A (en) 1987-12-17
US4826875A (en) 1989-05-02
ATE76747T1 (de) 1992-06-15
HUT43952A (en) 1988-01-28
AU605154B2 (en) 1991-01-10
US5017607A (en) 1991-05-21
EP0252290A3 (en) 1990-01-24
ES2042520T3 (es) 1993-12-16

Similar Documents

Publication Publication Date Title
KR890001533A (ko) 레보도파 메틸 에스테르를 함유하는 제약 조성물, 이들의 제조 및 치료학적 응용
KR920702216A (ko) 아세틸 d-카르니틴의 녹내장 치료에의 용도
DE69430132D1 (de) Pernasale zusammensetzung und diese enthaltende pernasale zubereitung
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
KR950007848A (ko) (S)-(-)-α-에틸-2-옥소-1-피롤리딘아세트아미드를 사용한 불안치료방법
KR940018089A (ko) 내부조직의 방사선 손상에 대한 예방 및 처치방법
KR970025615A (ko) 암 전이 억제제
KR910700045A (ko) Hiv 감염 관련 질병의 치료
ATE194987T1 (de) Substituierte dibenzoxazepinverbindungen, pharmazeutische zusammensetzungen und anwendungsmethoden
DK1201246T3 (da) Anvendelse af trombopoietin som et medikament til behandling og forebyggelse af trombocytopeni
KR910018020A (ko) 프라바스타틴과 피브르산 유도체의 혼합제. 및 이 혼합제를 사용한 이상지혈증 치료 방법
CO5160272A1 (es) Combinacion de cerivastatina y fibratos
KR830002510A (ko) 생물학적 활성화합물과 하이드록시알킬 전분으로 구성되는 조성물
KR890004705A (ko) 항바이러스성 제제
KR920702225A (ko) 약학 조성물
KR890701526A (ko) 각화증 치료제
ES2059348T3 (es) Composicion farmaceutica para el tratamiento de cataratas.
KR890007728A (ko) 진통제 제조방법
AR012972A1 (es) Forma farmaceutica para la administracion de paclitaxel, proceso para la preparacion de una composicion de paclitaxel lista para usar y uso de estacomposicion
KR870010871A (ko) 재조합 인체 알파 인터페론에 의한 기저세포 암종의 병소내적 치료방법
KR960003717A (ko) 항암제에 의해 유발되는 말초신경병의 예방에 유용한 의약의 제조를 위한 엘리프로딜 및 그 거울상이성질체의 이용
KR950700063A (ko) 외상후 스트레스 치료제로서의 브로파로민(Brofaromine as an agent for treating post-traumatic stress)
KR950701216A (ko) 레마세미드의 파킨슨병 치료 용도(use of remacemide for the treatment of parkinson's disease)
KR880000094A (ko) 위염치료제
KR930017579A (ko) 신경 보호제

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20090311

Year of fee payment: 15

EXPY Expiration of term